What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 3, Pre-Registered Trial).

December 8, 2025Blood

Extended treatment-free hospitalization-free time and quality of life benefits with CAR T-cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the KarMMa-3 trial

View Full Paper

Ask AI

Bookmark

Authors

MRMartina RaggiBristol-Myers Squibb (Switzerland)

Discussion

Member takes

Implication

Observational analysis revealed improved quality of life and reduced hospitalizations in patients with relapsed/refractory MM receiving CAR T-cell therapy, suggesting a major breakthrough.

Key Points

Patients receiving CAR T-cell therapy experienced significant improvements in quality of life metrics like EQ-5D index, along with reduced hospitalizations.
The treatment-free hospitalization-free time was markedly longer for CAR T-cell therapy compared to standard regimens, enhancing patient experience.
Assessment using event-free survival metrics demonstrated prolonged health states with greater overall benefit in patients treated with CAR T-cell therapy.
These findings highlight the potential for CAR T-cell therapy to transform therapeutic approaches in relapsed/refractory multiple myeloma.

Cite This Study

Martina Raggi (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1c1 https://doi.org/10.1182/blood-2025-5769

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis revealed improved quality of life and reduced hospitalizations in patients with relapsed/refractory MM receiving CAR T-cell therapy, suggesting a major breakthrough.

Extended treatment-free hospitalization-free time and quality of life benefits with CAR T-cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the KarMMa-3 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Extended treatment-free hospitalization-free time and quality of life benefits with CAR T-cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the KarMMa-3 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider